Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure
A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure
1 other identifier
interventional
136
2 countries
2
Brief Summary
This clinical study is a randomized, controlled, open, prospective, multi-centre, multi-surgeon post-market-clinical-follow-up study to investigate the impact of cataract grade on the efficacy and safety of femtosecond laser assisted lens fragmentation to support phacoemulsification of the cataractous lens prior to intraocular lens (IOL) implantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Oct 2013
Shorter than P25 for phase_4
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 23, 2013
CompletedFirst Posted
Study publicly available on registry
October 29, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2014
CompletedMarch 14, 2014
March 1, 2014
4 months
October 23, 2013
March 13, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Effective Phacoemulsification Time
The effective phacoemulsification time (EPT) used the "Laser group" (pooled from all grades) during phacoemulsification is lower than or equal to that in the "Manual group" (pooled from all grades); p\<0.05 will be considered statistically significant.
This criterion should be achieved at the day of treatment.
Secondary Outcomes (1)
Adverse Events
This purpose criterion should be achieved intraoperative, at 1 day, 1 week and 1 month.
Study Arms (2)
Femtosecond laser cataract surgery
EXPERIMENTAL"Laser group": a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure.
Manual cataract surgery
ACTIVE COMPARATOR"Manual": manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation
Interventions
The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens. The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process. Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status. All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.
"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Eligibility Criteria
You may qualify if:
- Patients must have read, understood and signed the Patient Information
- Patients are willing and able to return for follow-up examinations
- Clear corneal media
- Cataract grade (nuclear) from I to V according to LOCS III
- Patients must be at least 40 years of age
You may not qualify if:
- Patients presenting a clear lens (clear lens exchange)
- Glaucoma and suspected glaucoma
- Patients with pre-existing proliferative diabetic retinopathy (mild and tight controlled diabetes symptoms, without retinopathy and non-proliferative diabetic retinopathy, can be included.)
- Retinal disorders
- Rheumatic diseases
- Occlusion of retinal vessels
- Pellucid marginal degeneration
- Herpes zoster or herpes simplex keratitis
- Heavy vascularization of the ocular tissue
- Epilepsy
- Recurrent corneal erosion
- Severe basement membrane disease
- Patients who suffer from severe wound-healing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses,endocrine diseases, lupus, rheumatoid arthritis, collagenosis, or clinically significant atopy
- Patients suffering from AIDS or HIV.
- Chemosis
- +12 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Gemini Eye Clinic
Zlín, 76001, Czechia
MaxiVision Laser Centre Private Limited
Hyderabad, 500082, India
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pavel Stodulka, Dr. med
Gemini clinic, Zlin, Czech Republic 76001
- PRINCIPAL INVESTIGATOR
Kasu Prasad Reddy, MD
MaxiVision Laser Centre Private Limited, Hyderabad, India
- PRINCIPAL INVESTIGATOR
N Sreelakshmi, MD
MaxiVision Laser Centre Private Limited, Hyderabad, India
- STUDY CHAIR
Stephen Slade, MD
Slade & Baker Vision Center
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 23, 2013
First Posted
October 29, 2013
Study Start
October 1, 2013
Primary Completion
February 1, 2014
Study Completion
February 1, 2014
Last Updated
March 14, 2014
Record last verified: 2014-03